uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2018-25-2-7-18uzspbgmu-482Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМЕДИКО-ГЕНЕТИЧЕСКОЕ КОНСУЛЬТИРОВАНИЕ ПРИ НАСЛЕДСТВЕННЫХ ФОРМАХ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ И РАКА ЯИЧНИКОВMEDICAL AND GENETIC COUNSELING OF HEREDITARY BREAST AND OVARIAN CANCERЛаптиевС. А.LaptievS. A.

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

6-8 L’va Tolstogo str., Saint-Petersburg, 197022

telula87@gmail.comКорженевскаяМ. А.KorzhenevskaiaM. A.

Санкт-Петербург

Saint-Petersburg

korgmar@rambler.ruСоколенкоА. П.SokolenkoA. P.

Санкт-Петербург

Saint-Petersburg

annasokolenko@mail.ruИевлеваА. Г.IyevlevaA. G.

Санкт-Петербург

Saint-Petersburg

aglayai@inbox.ruИмянитовЕ. Н.ImyanitovE. N.

Санкт-Петербург

Saint-Petersburg

evgeny@imyanitov.spb.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияPavlov UniversityRussian FederationФедеральное государственное бюджетное учреждение «Научно-исследовательский институт онкологии имени Н. Н. Петрова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution «N. N. Petrov Institute of Oncology» of the Ministry of Healthcare of the Russian FederationRussian Federation201830062018252718Copyright © Лаптиев С.А., Корженевская М.А., Соколенко А.П., Иевлева А.Г., Имянитов Е.Н., 20182018Лаптиев С.А., Корженевская М.А., Соколенко А.П., Иевлева А.Г., Имянитов Е.Н.Laptiev S.A., Korzhenevskaia M.A., Sokolenko A.P., Iyevleva A.G., Imyanitov E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/482

Наследственный рак молочной железы и яичников является одной из самых распространенных генетических патологий. Медико-генетическое консультирование пациентов с наследственными формами рака и членов их семей является неотъемлемой составляющей оказания онкологической помощи, так как позволяет разработать комплекс диагностических, профилактических и лечебных мероприятий, направленных на наблюдение за здоровыми индивидуумами и создание персонифицированных подходов к лечению пациентов.

Hereditary breast and ovarian cancer is one of the most common genetic pathology. Medical and genetic counseling of patients with hereditary breast and ovarian cancer and their families plays the important role in cancer care, as it helps to develop the set of diagnostic, preventive and therapeutic measures aimed at monitoring healthy individuals and to create personalized approaches to the treatment of patients.

семейные формы раканаследственный рак молочной железы и рак яичниковгены BRCA 1/2медико-генетическое консультированиепрофилактикаfamilial cancerhereditary breast and ovarian cancergenes BRCA 1/2medical and genetic counselingpreventive careReferencesКаприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). – М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. – 250 с.Kaprin A.D., Starinskyi V.V., Petrova G.V. Malignant tumors in Russia in 2015 year (morbidity and mortality). М., «P. Herzen Moscow Oncology Research Institute» - branch of the FSBI «National Medical Research Radiological Center» of the Ministry of Healthcare of the Russian Federation. 2017; 250 pp. (in Russ.)Любченко Л. Н., Батенева Е. И. Медико-генетическое консультирование и ДНК-диагностика при наследственной предрасположенности к раку молочной железы и раку яичников. – М.: ИГ РОНЦ, 2014. – 75 с.Lyubchenko L.N., Bateneva E.I. Medical genetic counseling and DNA testing when hereditary predisposition to breast and ovarian cancer. М., FSBI «Russian Cancer Research Center named after N.N. Blokhin» of the Russian Ministry of Health. 2014; 75 pp. (in Russ.)Семиглазов В. Ф., Семиглазов В. В. Скрининг рака молочной железы // Практ. онкол. – 2010. – № 11 (2). – С. 60–65.Semiglazov V.F., Semiglazov V.V. Genetic screening in breast cancer. Pract. oncol. 2010; 11(2): 60-65. (in Russ.)Turnpenny P., Ellard S. Emery’s elements of human genetics. – 13th ed. – PA: Churchill Livingstone Elsevier, 2009. – 423 p.Turnpenny P., Ellard S. Emery’s elements of human genetics. PA, Churchill Livingstone Elsevier, 13th Ed. 2009; 423 pp.Имянитов Е. Н. Наследственный рак молочной железы // Практ. онкол. – 2010. – № 11. – С. 258–266.Imyanitov E.N. Hereditary breast cancer. Pract. oncol. 2010; 11: 258-266. (in Russ.)Lalwani N. et al. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment // J. Radiograph. – 2011. – № 31. – P. 625–646.Lalwani N. et al. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. J. Radiograph. 2011; 31: 625-646.Knudson A. Cancer genetics // Am. J. Med. Genet. – 2002. – № 111. – Р. 96–102.Knudson A. Cancer genetics. Amer. J. Med. Genet. 2002; 111: 96-102.Knudson A. et al. Mutation and cancer: statistical study of retinoblastoma // Proc. Natl. Acad. Sci. USA. – 1971. – № 68 (4). – Р. 820–823.Knudson A. et al. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 1971; 68(4): 820-823.Knudson A. et al. Two genetics hits (more or less) to cancer // Nature Rev. Can. – 2001. – № 1. – Р. 157–162.Knudson A. et al. Two genetics hits (more or less) to cancer. Nature Rev. Can. 2001; 1: 157-162.Соколенко А. П., Иевлева А. Г., Имянитов Е. Н. Что нужно знать о наследственном раке молочной железы и яичников. – СПб.: Эко вектор, 2016. – 48 с.Sokolenko A.P., Iyevleva A.G., Imyanitov E.N. What you need to know about hereditary breast and ovarian cancer. SPb., Eco Vector. 2016; 48 pp. (in Russ.)Groep P. et al. Pathology of hereditary breast cancer // Cell. Oncol. – 2011. – № 34. – Р. 71–88.Groep P. et al. Pathology of hereditary breast cancer. Cell Oncol. 2011; 34: 71-88.Ferla R. et al. Founder mutations in BRCA1 and BRCA2 genes // Ann. Oncol. – 2007. – № 18. – Р. 93–98.Ferla R. et al. Founder mutations in BRCA1 and BRCA2 genes. Ann. Oncol. 2007; 18: 93-98.Lynch H. et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology and management // Mol. Oncol. – 2009. – № 3. – Р. 97–137.Lynch H. et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology and management. Mol. Oncol. 2009; 3: 97-137.Narod S., Foulkes W. BRCA1 and BRCA2: 1994 and beyond // Nat. Rev. Cancer. – 2004. – № 4. – Р. 665–676.Narod S., Foulkes W. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer. 2004; 4: 665-676.Marchiò C., Reis-Filho J. Molecular diagnosis in Breast cancer // J. Diag. Histopathol. – 2008. – № 14 (5). – Р. 209–210.Marchiò C., Reis-Filho J. Molecular diagnosis in Breast cancer. J. Diag. Histopathol. 2008; 14(5): 209-210.Имянитов Е. Н. Скрининг для лиц с наследственной предрасположенностью к раку // Практ. онкол. – 2010. – № 11. – Р. 102–109.Imyanitov E.N. Screening in persons with hereditary predisposition to cancer. Pract. oncol. 2010; 11: 102-109.Pal T., Vadaparampil S. T. Genetic risk assessments in individuals at high risk for inherited Breast cancer in the Breast Oncology Care Setting // Can. Control. – 2012. – № 19 (4). – Р. 255–266.Pal T., Vadaparampil S.T. Genetic risk assessments in individuals at high risk for inherited Breast cancer in the Breast Oncology Care Setting. Can. Control. 2012; 19(4): 255-266.Ижевская В. Л., Козлова С. И. Медико-генетическое консультирование в России: некоторые этические аспекты // Мед. генетика. – 2004. – № 3. – Р. 370–375.Izhevskaya V.L., Kozlova S.I. Medical genetic counseling in Russia: some ethical aspects. Med. genet. 2004; 3: 370-375.Julie B. C. et al. BRCA1 and BRCA2 Hereditary Breast and Ovarian Canсer // Gene Rev. – 2001. – № 1. – P. 1–19.Julie B.C. et al. BRCA1 and BRCA2 Hereditary Breast and Ovarian Canсer. Gene Rev. 2001; 1: 1-19.Имянитов Е. Н., Хансон К. П. Молекулярная онкология: клинические аспекты. – СПб.: МАПО, 2007. – 210 с.Imyanitov E.N., Hanson K.P. Molecular oncology: clinical aspects. SPb., Medical Academy of Postgraduate Education. 2007; 210 pp. (in Russ.)Andrieu N. et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study // J. Nat. Cancer Inst. – 2006. – № 98. – Р. 535–544.Andrieu N. et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. J. Nat. Cancer Inst. 2006; 98: 535–544.Schattman G., Stubbs R. Options, risks and chances for success preserving fertility in women with BRCA gene mutations // Sexuality Reprod. Menopaus. J. – 2011. – № 9 (4). – Р. 20–25.Schattman G., Stubbs R. Options, risks and chances for success preserving fertility in women with BRCA gene mutations. Sexuality Reprod. Menopaus. J. 2011; 9(4): 20-25.Narod S. et al. Oral contraceptives and the risk of hereditary ovarian cancer // N. Eng. J. Med. – 1998. – № 339 (7). – Р. 424–428.Narod S. et al. Oral contraceptives and the risk of hereditary ovarian cancer. N. Eng. J. Med. 1998; 339(7): 424-428.Balmaña J. et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines // Ann. Oncol. – 2010. – № 21. – Р. 20–22.Balmaña J. et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 2010; 21: 20-22.Rebbeck T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations // Hum. Mutat. – 2018. – № 39 (5). – P. 593–620.Rebbeck T.R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 2018; 39(5): 593-620.Robson M. E. et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility // J. Clin. Oncol. – 2015. – № 28. – P. 893–901.Robson M.E. et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J. Clin. Oncol. 2015; 28: 893-901.Position Statement on BRCA Genetic Testing for Patients with and without Breast Cancer // The Am. Soc. of Br. Surg. Resear. Commit. – 2012.Position Statement on BRCA Genetic Testing for Patients With and Without Breast Cancer. The Amer. Soc. of Br. Surg. Resear. Commit. 2012.Sokolenko A. P., Iyevleva A. G., Imyanitov E. N. Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing // Hered. Can. Clin. Pract. – 2009. – № 7 (1). – Р. 2.Sokolenko A.P., Iyevleva A.G., Imyanitov E.N. Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. Hered. Can. Clin. Pract. 2009; 7(1): 2.Daly M. B. et al. NCCN Guidelines Insights: Genetic/ Familial High-Risk Assessment: Breast and Ovarian, Version 2. 2017 // J. Natl. Compr. Canc. Netw. – 2017. – № 15. – P. 9–20.Daly M.B. et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J. Natl. Compr. Canc. Netw. 2017; 15: 9-20.Leach M. et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicenter cohort study // Lancet. – 2005. – № 365. – Р. 1769–1778.Leach M. et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicenter cohort study. Lancet. 2005; 365: 1769-1778.Domchek S. M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality // J. Am. Med. Ass. – 2010. – № 304 (9). – Р. 967–975.Domchek S.M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J. Amer. Med. Ass. 2010; 304(9): 967-975.De Felice F. et al. Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis // Ann. Surg. Oncol. – 2015. – № 22 (9). – P. 2876–2880.De Felice F. et al. Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis. Ann. Surg. Oncol. 2015; 22(9): 2876-2880.Meijers-Heijboer H. et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation // N. Engl. J. Med. – 2001. – № 345. – Р. 159–164.Meijers-Heijboer H. et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001; 345: 159-164.Hartmann L. N., Lindor N. M. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer // N. Eng. J. Med. – 2016. – № 374. – P. 454–468.Hartmann L.N., Lindor N.M. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N. Eng. J. Med. 2016; 374: 454-468.Long K., Kauff N. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies // Curr. Opin. Oncol. – 2011. – № 23. – Р. 526–530.Long K., Kauff N. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr. Opin. Oncol. 2011; 23: 526-530.Rodriguez-Wallberg K. A., Oktay K. Fertility preservation in women with breast cancer // Clin. Obstet. Gynecol. – 2010. – № 53 (4). – Р. 753–762.Rodriguez-Wallberg K. A., Oktay K. Fertility preservation in women with breast cancer. Clin. Obstet. Gynecol. 2010; 53(4): 753-762.Lee S. J. et al. Recommendations on fertility preservation in cancer patients. ASCO // J. Clin. Oncol. – 2006. – № 24 (18). – Р. 2917–2931.Lee S.J. et al. Recommendations on fertility preservation in cancer patients. ASCO. J. Clin. Oncol. 2006; 24(18): 2917-2931.Fisk N. M. et al. Lack of effect of high-dose antioestrogen on the maturation and in vitro fertilization of human oocytes // Hum. Reprod. – 1989. – № 4 (5). – Р. 584–587.Fisk N.M. et al. Lack of effect of high-dose antioestrogen on the maturation and in-vitro fertilization of human oocytes. Hum. Reprod. 1989; 4(5): 584-587.Polyzos N. P. et al. Aromatase inhibitors for female infertility: a systematic review of the literature // Reprod. Biomed. – 2009. – № 19 (4). – Р. 456–471.Polyzos N.P. et al. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod. Biomed. 2009; 19(4): 456-471.Kotsopoulos J. et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study // Can. Causes Control. – 2008. – № 19 (10). – Р. 1111–1119.Kotsopoulos J. et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Can. Causes Control. 2008; 19(10): 1111-1119.Oktay K. et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks // J. Clin. Oncol. – 2010. – № 28 (2). – Р. 240–244.Oktay K. et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J. Clin. Oncol. 2010; 28(2): 240-244.

The authors declare that there are no conflicts of interest present.